Treatment Response and Survival in Thyroid Transcription Factor‐1 Negative Non‐squamous Non‐small Cell Lung Cancer
In the treatment of TTF-1-negative NS-NSCLC, platinum-based combination therapy, particularly with the addition of bevacizumab, improved response rates and led to prolonged survival.
Authors
- Yutaka Takahara (ORCID: https://orcid.org/0000-0001-6863-0074)
- Yoko Ishige
- Masaharu Iguchi
- Masafumi Nojiri
- Ikuyo Shionoya
- Takuya Tanaka (ORCID: https://orcid.org/0000-0003-2578-4510)
- Sumito Nagae
- Kouichi Yamamura
- Ryudai Abe
Institutions
- Kanazawa Medical University (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-09-01
- DOI
- https://doi.org/10.21873/cdp.10472
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00